# Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections

> **NCT00102947** · PHASE4 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 72 (—)

## Conditions studied

- Soft Tissue Infections

## Interventions

- **DRUG:** daptomycin (up to 14 days)

## Key facts

- **NCT ID:** NCT00102947
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 72 (—)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102947, "Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00102947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*